These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 26156586)

  • 1. The effects and mechanisms of SLC34A2 in tumorigenesis and progression of human non-small cell lung cancer.
    Wang Y; Yang W; Pu Q; Yang Y; Ye S; Ma Q; Ren J; Cao Z; Zhong G; Zhang X; Liu L; Zhu W
    J Biomed Sci; 2015 Jul; 22(1):52. PubMed ID: 26156586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-410 acts as oncogene in NSCLC through downregulating SLC34A2 via activating Wnt/β-catenin pathway.
    Zhang X; Ke X; Pu Q; Yuan Y; Yang W; Luo X; Jiang Q; Hu X; Gong Y; Tang K; Su X; Liu L; Zhu W; Wei Y
    Oncotarget; 2016 Mar; 7(12):14569-85. PubMed ID: 26910912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockdown of SLC34A2 inhibits cell proliferation, metastasis, and elevates chemosensitivity in glioma.
    Bao Z; Chen L; Guo S
    J Cell Biochem; 2019 Jun; 120(6):10205-10214. PubMed ID: 30592329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated expression of SLC34A2 inhibits the viability and invasion of A549 cells.
    Yang W; Wang Y; Pu Q; Ye S; Ma Q; Ren J; Zhong G; Liu L; Zhu W
    Mol Med Rep; 2014 Sep; 10(3):1205-14. PubMed ID: 25017204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knockdown of SLC34A2 Inhibits Hepatocellular Carcinoma Cell Proliferation and Invasion.
    Li Y; Chen X; Lu H
    Oncol Res; 2016 Oct; 24(6):511-519. PubMed ID: 28281971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SLC34A2 simultaneously promotes papillary thyroid carcinoma growth and invasion through distinct mechanisms.
    He J; Zhou M; Li X; Gu S; Cao Y; Xing T; Chen W; Chu C; Gu F; Zhou J; Jin Y; Ma J; Ma D; Zou Q
    Oncogene; 2020 Mar; 39(13):2658-2675. PubMed ID: 32005974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects and mechanisms of SLC34A2 on tumorigenicity in human non-small cell lung cancer stem cells.
    Jiang Z; Hao Y; Ding X; Zhang Z; Liu P; Wei X; Xi J
    Tumour Biol; 2016 Aug; 37(8):10383-92. PubMed ID: 26846105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long non-coding RNA MEG3 regulates migration and invasion of lung cancer stem cells via miR-650/SLC34A2 axis.
    Zhao Y; Zhu Z; Shi S; Wang J; Li N
    Biomed Pharmacother; 2019 Dec; 120():109457. PubMed ID: 31585300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-629 promotes the tumorigenesis of non-small-cell lung cancer by targeting FOXO1 and activating PI3K/AKT pathway.
    Zhu L; Chen Y; Liu J; Nie K; Xiao Y; Yu H
    Cancer Biomark; 2020; 29(3):347-357. PubMed ID: 32716350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circular RNA F-circSR derived from SLC34A2-ROS1 fusion gene promotes cell migration in non-small cell lung cancer.
    Wu K; Liao X; Gong Y; He J; Zhou JK; Tan S; Pu W; Huang C; Wei YQ; Peng Y
    Mol Cancer; 2019 May; 18(1):98. PubMed ID: 31118036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
    Gao BB; Wang SX
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of SLC34A2 is an independent prognostic indicator in bladder cancer and its depletion suppresses tumor growth via decreasing c-Myc expression and transcriptional activity.
    Ye W; Chen C; Gao Y; Zheng ZS; Xu Y; Yun M; Weng HW; Xie D; Ye S; Zhang JX
    Cell Death Dis; 2017 Feb; 8(2):e2581. PubMed ID: 28151475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer.
    Zhou Y; Li S; Li J; Wang D; Li Q
    Cell Physiol Biochem; 2017; 42(4):1431-1446. PubMed ID: 28715819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FAM83A is amplified and promotes tumorigenicity in non-small cell lung cancer via ERK and PI3K/Akt/mTOR pathways.
    Hu H; Wang F; Wang M; Liu Y; Wu H; Chen X; Lin Q
    Int J Med Sci; 2020; 17(6):807-814. PubMed ID: 32218702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracellular vesicle-encapsulated microRNA-425-derived from drug-resistant cells promotes non-small-cell lung cancer progression through DAPK1-medicated PI3K/AKT pathway.
    Guo Z; Ye H; Zheng X; Yin W; He J
    J Cell Physiol; 2021 May; 236(5):3808-3820. PubMed ID: 33258116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circular RNA circ-PLCD1 functions as a tumor suppressor in non-small cell lung cancer by inactivation of PI3K/AKT signaling pathway.
    Si J; Jin J; Sai J; Liu X; Luo X; Fu Z; Wang J
    Hum Cell; 2022 May; 35(3):924-935. PubMed ID: 35301686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphatidylethanolamine-binding protein 4 promotes the epithelial-to-mesenchymal transition in non-small cell lung cancer cells by activating the sonic hedgehog signaling pathway.
    Jian W; Bai Y; Li X; Kang J; Lei Y; Xue Y
    J Cell Biochem; 2019 Apr; 120(4):5386-5395. PubMed ID: 30367510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The high expression of MTH1 and NUDT5 promotes tumor metastasis and indicates a poor prognosis in patients with non-small-cell lung cancer.
    Li DN; Yang CC; Li J; Ou Yang QG; Zeng LT; Fan GQ; Liu TH; Tian XY; Wang JJ; Zhang H; Dai DP; Cui J; Cai JP
    Biochim Biophys Acta Mol Cell Res; 2021 Jan; 1868(1):118895. PubMed ID: 33096144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-107 inhibits tumor growth and metastasis by targeting the BDNF-mediated PI3K/AKT pathway in human non-small lung cancer.
    Xia H; Li Y; Lv X
    Int J Oncol; 2016 Oct; 49(4):1325-33. PubMed ID: 27498977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway.
    Wei C; Dong X; Lu H; Tong F; Chen L; Zhang R; Dong J; Hu Y; Wu G; Dong X
    J Exp Clin Cancer Res; 2019 Feb; 38(1):95. PubMed ID: 30791942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.